Posted by David T. Drummond ⎜Jun 9, 2019 ⎜ Calendar
11th International Symposium on Targeted-Alpha-Therapy, April 1-5, 2019 in Ottawa, Ontario, Canada. isoSolutions is pleased to inform you that we will attend the 11th International Symposium on Targeted-Alpha-Therapy (TAT11). You can find us at booth 28 the Exhibit Hall at the Fairmont Chateau Laurier.
Neil Shirley, Sales Manager, United States and Canada, hopes to see you there. If you would like to arrange a time to meet with Neil, please contact him at email@example.com
Hope to see you in Ottawa, Ontario.
Posted by David T. Drummond ⎜Jun 8, 2019 ⎜ Calendar
SNMMI 2019 Annual Meeting, June 22-25, 2019 in Anaheim, California.
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). (more…)
Posted by David T. Drummond ⎜Apr 25, 2019 ⎜ Company
In order to strengthen its position in the Asian market, isoSolutions has appointed a Sales and Marketing Manager for Asia. Mr. Eric Chang will be responsible for sales and marketing efforts in the Asian market. He will be supported by Mr. Hans Peng, Sales and Marketing Manager, China and Mr. Eric Huang, Sales and Marketing Representative, China (located in Shanghai). (more…)
Posted by David T. Drummond ⎜Apr 22, 2019 ⎜ Industry
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a down-stream effect of AR activity is a promising rationale for management of this disease. (more…)
Posted by Kevin Yang ⎜Mar 25, 2019 ⎜ Industry
5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.
Posted by Kevin Yang ⎜Feb 25, 2019 ⎜ Industry
The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and 177Lu-DOTATATE in malignant PGL patients. (more…)
Posted by David T. Drummond ⎜Feb 21, 2019 ⎜ Industry
Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. (more…)
Posted by David T. Drummond ⎜Feb 18, 2019 ⎜ Company
Vancouver and Buenos Aires, February 2019
We are very proud to announce a new strategic commercial Alliance between isoSolutions and Fenix Medica for the Latin American market. isoSolutions provides a one-stop shopping service as well as technical support worldwide for nuclear medicine products including: Radiochemicals, Stable isotopes, Labeled compounds, Sealed sources, Synthesizers, QC instruments, and Shielding products. (more…)
Tags: Latin America
Posted by Kevin Yang ⎜Feb 13, 2019 ⎜ Industry
Bone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. (more…)
Posted by David T. Drummond ⎜Feb 5, 2019 ⎜ Company
Chinese Lunar New Year
isoSolutions wishes everyone health and prosperity in the Year of the Pig!
Posted by Marvin Calderon ⎜Jan 13, 2019 ⎜ Calendar
isoSolutions will be attending the ALASBIMN 2019 Annual Meeting to be held in Lima, Peru November 13 to 16, 2019. Marvin Calderon, Regional Sales and Marketing Manager Sales for Latin America hopes to see you there. If you would like to arrange a time and place to meet him, please contact firstname.lastname@example.org.
Posted by Patricia Acton ⎜Jan 13, 2019 ⎜ Calendar
isoSolutions will be attending the CANM 2019 Annual Meeting to be held in Québec, QC, Canada February 07 to 09, 2019. Pat Acton, Regional Sales and Marketing Manager Sales for Canada and US hopes to see you there. If you would like to arrange a time and place to meet her, please contact email@example.com.
Posted by David T. Drummond ⎜Nov 20, 2018 ⎜ Industry
The worldwide supply of molybdenum-99 is expected to stabilize over the next several weeks as the High Flux Reactor in the Netherlands and the Open Pool Australian Lightwater nuclear reactor have resumed operations and are expected to reach normal Mo-99 production this week. Meanwhile, NTP Radioisotopes’ South Africa-based Pelindaba Nuclear Plant, which has finished functionality tests, is awaiting approval from the country’s National Nuclear Regulator to begin Mo-99 production runs.
Posted by David T. Drummond ⎜Nov 19, 2018 ⎜ Industry
An agreement signed with SpectronRx, an Indiana, USA radiopharmaceutical manufacturer, designates isoSolutions as the exclusive distributor in Latin America and Canada of Spectron’s GMP grade non-carrier added (nca) Lutetium-177 radiochemical.
Non-carrier added (nca) Lutetium-177 (Lu-177) is a radioisotope used for therapeutic purposes. (more…)
Posted by Kevin Yang ⎜Nov 5, 2018 ⎜ Industry
Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. (more…)
Posted by David T. Drummond ⎜Oct 29, 2018 ⎜ Industry
A generous donor has given the B.C. Cancer Foundation $18.346 million, but insists on remaining anonymous.
“Today marks an important moment in cancer research and care in Canada with one of the largest donations ever made to bring new treatment solutions to patients,” said Sarah Roth, president and CEO of the B.C. Cancer Foundation. (more…)
Posted by Kevin Yang ⎜Sep 21, 2018 ⎜ Industry
INTRODUCTION: Prostate-specific membrane antigen (PSMA) is an excellent prostate cancer target for theranostic applications. Many imaging agents showing high sensitivity/specificity for PSMA-expressing tissues have been developed. Some have been labeled with therapeutic radionuclides (i.e. 177Lu, 225Ac) and have had success in treating castration-resistant metastatic prostate cancer. The activity administered to patients is limited by toxicity to normal organs;
Posted by Kevin Yang ⎜Sep 12, 2018 ⎜ Industry
This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted. (more…)
Posted by Kevin Yang ⎜Sep 6, 2018 ⎜ Industry
Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)
Posted by Patricia Acton ⎜Sep 5, 2018 ⎜ Calendar
isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018. (more…)
Tags: Batch Reporting System Beta detection Beta flow monitor Beta radio-detector Cassette-based synthesis Chromatography Software Clarity Elysia-raytest Ga-68 synthesis Gamma detection Gamma flow monitor Gamma radio-detector Gamma spectroscopy Gas Chromatography GC systems HPLC isoSolutions LIMS Liquid Scintillation Liquid Scintillation Pump Lu-177 MCA Multichannel analyzer North America Nuclear Medicine PET QC QC-Cubicle Quality Control Radio Detector Radio nuclide identification Radio nuclide purity radio spectroscopy radio TLC scanners radio-flow monitor radio-HPLC radio-synthesis radio-TLC Systems Radio-tracer Radiopharmaceutical Tracer Radiopharmaceuticals Radiopharmacy Residual Solvents Control Single-use cassette synthesis SPECT QC Spectroscopy Software Sterile filter integrity test Sterility Filter Test Synthesis Modules Synthesizers Tradeshows UPPI
Posted by Hans Peng ⎜Aug 2, 2018 ⎜ Industry
Since China was the highlighted country of 2018 SNMMI in Philadelphia, several CSNM board members presented a brief report of 2018 SNMMI to the audience. One interesting fact needs attention is that Lu-177 is the most discussed topic this year not only because Lu-177 is highly in demand during SNMMI, but also more and more professors and doctors in China have realized how important and effective Lu-177 is when it is used to diagnose and treat prostate cancer. (more…)
Posted by Kevin Yang ⎜Jul 26, 2018 ⎜ Industry
Y-90 radioembolization for HCC patients with PVT appears to have an acceptable safety profile, with better survival in CP-A patients than in CP-B patients. This study confirms prior reports of survival in PVT patients treated with Y-90 radioembolization, and survival after Y-90 radioembolization appears to exceed that in
similar patients treated with systemic therapies. Despite the negative studies recently reported, Y-90 radioembolization is a reasonable treatment option in properly selected PVT patients. Further controlled studies are needed to compare it with systemic therapies or other locoregional treatments for advanced-stage HCC.
Nadine Abouchaleh1, Ahmed Gabr1, Rehan Ali1, Ali Al Asadi1, Ronald A. Mora1, Joseph Ralph Kallini1, Samdeep Mouli1, Ahsun Riaz1, Robert J Lewandowski1, and Riad Salem1–3
Info on purchasing Y-90, please contact firstname.lastname@example.org
Read the full article PDF
Posted by Hans Peng ⎜Jul 11, 2018 ⎜ Calendar
The Chinese Society of Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from 2018–07–12 to 2018–07–15. We hope to see you there and we can arrange a time and place to meet if you wish.
Posted by Hans Peng ⎜Jul 11, 2018 ⎜ Industry
isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine (http://www.csnm.com.cn/) in Sichuan, China.
The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. (more…)
Posted by David T. Drummond ⎜Jun 29, 2018 ⎜ Industry
PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). (more…)
Posted by David T. Drummond ⎜Jun 11, 2018 ⎜ Industry
By Wayne Forrest, AuntMinnie.com staff writer.
Major changes are taking place in the intricate network that supplies healthcare providers around the world with molybdenum-99 (Mo-99), a key radioisotope for nuclear medicine studies. The question is, can the nuclear medicine community avoid another devastating shutdown like the one that occurred in 2009? (more…)
Posted by Kevin Yang ⎜Jun 6, 2018 ⎜ Industry
A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.
Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2
Info on purchasing Ac-225, please contact email@example.com .
Posted by David T. Drummond ⎜May 7, 2018 ⎜ Industry
The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students. This scholarship is granted to a student at Langara College in Vancouver. To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in Marketing.
Posted by David T. Drummond ⎜Apr 25, 2018 ⎜ Industry
PET/CT-guided percutaneous biopsy can be safely and accurately performed within the PET/CT suite without reinjection of the 89Zr-labeled radiotracer after the initial injection for diagnostic imaging. 89Zr-labeled radiotracers targeting specific proteins may be useful for both detection and molecular profiling in high-risk patients presenting with widely disseminated disease. Studies such as this may add clinical justification for the use of molecular imaging in interventional oncology and for promoting future access to interventional PET imaging facilities. (more…)
Posted by David T. Drummond ⎜Apr 6, 2018 ⎜ Industry
Key findings of the study:
Posted by Kevin Yang ⎜Mar 20, 2018 ⎜ Industry
99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using 99mTc -sestamibi for patients with coronary artery disease.
The WATERDAY study: Denis Agostini & Vincent (more…)
Posted by David T. Drummond ⎜Mar 14, 2018 ⎜ Industry
During the last decade, the utilization of 68Ga for the development of imaging agents has increased considerably with the leading position in the oncology. The imaging of infection and inflammation is lagging despite strong unmet medical needs. This review presents the potential routes for the development of 68Ga-based agents for the imaging and quantification of infection and inflammation in various diseases and connection of the diagnosis to the treatment for the individualized patient management. (more…)
Posted by Kevin Yang ⎜Mar 12, 2018 ⎜ Industry
Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)
Posted by David T. Drummond ⎜Feb 14, 2018 ⎜ Industry
The first Peptide Receptor Radionuclide Therapy (PRRT) has received FDA approval. Lutetium 177 DOTA-TATE (Lu 177), a type of PRRT, is now approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors in adults.
FDA approval of PRRT using Lu-177 will allow more eligible U.S. patients to receive this “life extending” treatment. Lu-177 is manufactured by Advanced Accelerator Applications (AAA), a Novartis company. Prior to the FDA approval, PRRT with Lu-177 was only available in a limited number of American treatment centers as part of an expanded access program or through a clinical trial.
Click here to see full news release.
Posted by David T. Drummond ⎜Feb 1, 2018 ⎜ Products
IRE is proud to announce a partnership with ASML to further develop a new, non-fission production method for medical isotopes such as Mo-99/Tc-99m. This partnership has resulted in the start of the LightHouse Isotopes BV, an ambitious initiative for the development of a promising alternative production method for a sustainable long term supply of Mo-99.
Click here to see full post.
Posted by David T. Drummond ⎜Jan 19, 2018 ⎜ Calendar
2018 June 23 to 26 @ Pennsylvania Convention Center, Headquarter Hotel: Philadelphia Marriott
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). You can find us at Booth 1001 in the Pennsylvania Convention Center. We hope to see you there and we can arrange a time and place to meet if you wish.
We look forward to seeing you in Philadelphia, Pennsylvania.
Posted by David T. Drummond ⎜Jan 19, 2018 ⎜ Calendar
isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Vancouver, BC from 2018–03–23 to
More info about the event on canm-acmn.ca
Posted by Kevin Yang ⎜Jan 11, 2018 ⎜ Industry
Transcatheter hepatic artery embolization therapy is a minimally invasive alternative for treating inoperable liver cancer, but recurrence is frequent. Multifunctional agents could offer an opportunity for tumor eradication. In this article, the researchers aimed to synthesize poly (lactic-co-glycolic acid) (PLGA) microspheres encapsulating hollow CuS nanoparticles (HCuSNPs) and paclitaxel (PTX) that were then labeled with radioiodine-131 (131I) to produce 131I-HCuSNPs-MS-PTX. (more…)
Posted by Hans Peng ⎜Dec 21, 2017 ⎜ Industry
温哥华，不列颠哥伦比亚省(2018) isoSolutions 是集中核医学，放射性同位素研究和核药工业为一体的全球供应商，现宣布在中国推出Elysia-raytest放射性药物质量控制仪器。
Posted by Hans Peng ⎜Dec 21, 2017 ⎜ Industry
isoSolutions begins 2018 Representation of Elysia-raytest Quality Control Instruments in CHINA. isoSolutions, a global provider to the nuclear medicine, radioisotope research, and pharmaceutical industries, announces the launch of its representation of the Elysia-raytest radiopharmaceutical Quality Control instrumentation in China.
isoSolutions representation agreement includes Elysia-raytest’s traditional instrument line, as well as, the all new, all-in-one QC-Cubicle Quality Control laboratory for the production of radiopharmaceuticals. (more…)
Posted by David T. Drummond ⎜Nov 6, 2017 ⎜ Industry
Radioimmunotherapy of solid tumors using antibody-targeted radionuclides has been limited by low therapeutic indices (TIs). The article below recently reported a novel 3-step pretargeted radioimmunotherapy (PRIT) strategy based on a glycoprotein A33 (GPA33)–targeting bispecific antibody and a small-molecule radioactive hapten (more…)
Posted by David T. Drummond ⎜Nov 3, 2017 ⎜ Company
Mr. Gabriel Freitas has been appointed as the Customer Service Manager for isoSolutions. This new position provides general administrative support to the team, with primary responsibility for customer and supplier support. The main responsibilities of this position are to maintain the order desk and customer support.The Customer Service Manager will prepare quotations; receive, enter, acknowledge and distribute purchase orders and invoices; check and distribute shipping documents; process order changes; and correspond with suppliers, customers and sales managers regarding orders and new product requests. Other duties will include organizing tradeshows and logistics for tradeshows; coordinating website maintenance; preparing and distributing newsletters; managing promotional brochures; and assisting with staff training programs. (more…)
Posted by David T. Drummond ⎜Oct 24, 2017 ⎜ Company
“Vancouver, BC – The Western Region Society of Nuclear Medicine (WRSNM) will honor Dr. François Bénard from the BC Cancer Agency with the presentation of their Distinguished Scientist Award. … Dr. Bénard is the Vice President, Research at the BC Cancer Agency, a Distinguished Scientist at the BC Cancer Agency Research Centre and Professor in the Department of Radiology at the University of British Columbia. He is also Associate Dean, Research at the University of British Columbia. In addition he holds the BC Leadership Chair in Functional Cancer Imaging. As a clinician scientist, his research interests are in positron emission tomography (PET), nuclear medicine, cancer imaging and targeted radionuclide therapy. (more…)
Posted by David T. Drummond ⎜Oct 3, 2017 ⎜ Industry
A recipient of the Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, was selected by Langara College to address scholarship donors on behalf of students at the Donor Recognition event.
Mr. Hazhir Goodarznia was awarded the scholarship last March as a science student who completed a course in marketing. The scholarship highlights the importance of marketing and sales of high-technology, scientifically-intensive products. It honors Brian Armstrong and Will Lepeska, who were pioneers in the new field of nuclear medicine and who, as scientists, focused their efforts on the marketing and sales of medical products. They played a critical role in bringing medical developments from the laboratory to the public and to common usage. (more…)
Posted by Patricia Acton ⎜Aug 16, 2017 ⎜ Calendar
isoSolutions is pleased to inform you that we will exhibit at the 2017 Western Region Society of Nuclear Medicine Annual Meeting held at the Westin BayShore in Vancouver, British Columbia from 2017–11–03 to 2017–11–05. We hope to see you there and we can arrange a time and place to meet if you wish.
Posted by Hans Peng ⎜Aug 15, 2017 ⎜ Calendar
isoSolutions is pleased to inform you that our Japanese marketing assistant will attend the The 12thAsia Oceania Congress of Nuclear Medicine and Biology on October 5-7 in Yokohama, Japan.
We hope to see you there and we can arrange a time and place to meet if you wish. We look forward to seeing you in Yokohama, Japan. (more…)
Posted by Hans Peng ⎜Jun 27, 2017 ⎜ Products
isoSolutions announces the launch of its representation of the Hake Medical Hot Cell, Fume Hood and Shielding Accessories in North and Latin America. In partnership with Hake Medical, isoSolutions is able to provide a complete solution for your radiation protection needs.
In 2016, Hake Medical became the first publically listed company in the field of radiation protection and shielding in China. Hake Medical focuses on providing radiation protection and shielding to nuclear medicine (more…)
Posted by David T. Drummond ⎜Jun 2, 2017 ⎜ Calendar
2017 June 10 to 14 @ The Colorado Convention Center, 700 14th St, Denver, CO 80202
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). You can find us at Booth 931 in the Colorado Convention Center. We hope to see you there and we can arrange a time and place to meet if you wish.
We look forward to seeing you in Denver, Colorado.
Posted by David T. Drummond ⎜Jun 2, 2017 ⎜ Calendar
The Chinese Society of Nuclear Medicine Annual Meeting will be held at Zunyi, Guizhou Province from 2017–06–29 to 2017–07–01.
Posted by David T. Drummond ⎜Apr 1, 2017 ⎜ Calendar
isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Toronto, Ontario from 2017–04–20 to
Posted by David T. Drummond ⎜Mar 29, 2017 ⎜ Industry
The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students.
This scholarship is granted to a student at Langara College in Vancouver. To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in marketing. This year, two students were funded: Mr. Hazhir Goodarznia and Mr. Adrian Wong (more…)
Posted by David T. Drummond ⎜Feb 2, 2017 ⎜ Industry
isoSolutions, a global provider to the nuclear medicine, Radioisotope research, and Pharmaceutical industries, announces the launch of its representation of the Elysia-Raytest Radiopharmaceutical quality control instrumentation in north and latin america.
The isoSolutions representation agreement includes Elysia-Raytest’s traditional instrument line, as well as the all new, All-In-One QC-Cubicle Quality Control Laboratory (more…)
Posted by David T. Drummond ⎜Jan 24, 2017 ⎜ Industry
isoSolutions, a global provider to the nuclear medicine, radioisotope research, and pharmaceutical industries, and partner Europe-based Elysia-raytest (www.elysia-raytest.com) will jointly market Oxygen-18 water.
Special reduced pricing conditions are currently available for purchase of the O-18 Water.
Nukem O-18 Water Features:
Isotopic enrichment: >98%
Chemical purity: >98%; conductivity: 2µS/cm; free of NH4 (different enrichment technology)
Quality standards: cGMP approved production facility; sterile and pPyrogen-free product; ISO 9001:2000 certification
Enrichment process: Cryo-distillation of NO; tritium-free; no use of recycled water (to eliminate tritium contamination)
Posted by David T. Drummond ⎜Jan 18, 2017 ⎜ Industry
isoSolutions, a global provider to the nuclear medicine, radioisotope research, and pharmaceutical industries, today announced the launch of the Elysia-raytest GAIA Ga-68 Synthesizer in North and Latin America. In partnership with Elysia-raytest, isoSolutions supplies a Ga-68 generator compatible with the GAIA Ga-68 Synthesizer. It is now possible to offer a complete Ga-68 labeling package to all isoSolutions customers in the Americas.
Special pricing conditions are currently available for purchase of the GAIA Ga-68 Synthesizer.
The GAIA Synthesizer, a GMP Peptide Labeling Fluidic Processor, is utilized for the labeling of peptides such as DOTAToc with radioactive metals (e.g. 68Ga). It utilizes single-use synthesis kits optimized for fast and simple production of common tracers. (more…)
Posted by David T. Drummond ⎜Jan 12, 2017 ⎜ Industry
isoSolutions, a global provider to the nuclear medicine, radioisotope research, pharmaceutical and medical device industries has formalized an agreement with Europe-based Elysia-raytest as distributor for their line-up of nuclear medicine/PET laboratory instruments in the North American and South American markets. The combined product offerings of the partnership will allow isoSolutions to become a complete solution provider for the nuclear medicine/PET community. (more…)
Posted by David T. Drummond ⎜Dec 27, 2016 ⎜ Company
To reflect additions to our product line and expansion of our business, isoSolutions will install a new, updated web site early in 2017. The new web site will incorporate new features that will be of interest to our visitors and will help our clients and partners to find the information they are seeking.
The new web site will be designed and installed by Mr. Bruno Tomazelli, who has joined our team. Bruno is a graphic designer with over five years of experience in advertising. (more…)
Posted by David T. Drummond ⎜Nov 15, 2016 ⎜ Products
Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible manner. The aim of this study was to develop automated synthesis methods for these six 18F-labeled radiopharmaceuticals produced on a routine basis at the University of Pennsylvania using (more…)
Posted by David T. Drummond ⎜Nov 1, 2016 ⎜ Industry
We regret to announce that Dr. Alexander Susan has passed away peacefully at the age of 83 in Columbia, Missouri. In 2001, Alex Susan and David Drummond, the principal of isoSolutions, formed a joint company – Alpha IICH Inc. – to develop a supply of alpha emitting radionuclides to researchers for therapeutic applications. Over the years, Alex and David pursued many business opportunities together, merging their international networks of contacts for mutual benefit. Alex became a friend as well as a loyal partner. He will be missed. (more…)
Posted by David T. Drummond ⎜Nov 1, 2016 ⎜ Calendar
isoSolutions will be present at the Brazilian Nuclear Medicine Congress from 2016–11–12 to 2016–11–14.